Is the ABO Blood Group a Predictor of Renal Allograft Survival in ABO Identical Donor Recipients?
Ertay Boran, Mediha Boran
Abstract
Ertay Boran, Mediha Boran
Abstract
Objective: The effect of the ABO blood group on renal allograft survival (AS) is unclear. We assessed the influence of the ABO blood group on AS and performed a comparative analysis of AS in kidney transplant recipients with different ABO blood groups. Methods: The 239 renal transplant recipients who underwent transplantation in a single center were stratified into the 3 groups: blood group O (84, 35.14%), blood group A (104, 43.51%), and due to the low number of blood group AB patients, blood groups B and AB were classified as blood group B (51, 21.3%). Clinical outcomes and patient demographics were investigated and compared between groups. Results: The AS of blood group O recipients was significantly longer than that of blood group B recipients (P = .001). Correlation analyses revealed that recipient age (P = .002), donor age (P = .013), creatinine level (P = .022), estimated glomerular filtration rate (eGFR) (P = .005), human leukocyte antigen (HLA) mismatches (P = .001), blood group O (P < .0001), blood group B (P < .0001), cyclosporine A (P < .0001), and sirolimus treatment (P = .032) were predictors of AS. Multivariate regression analyses indicated that blood group B (β = −0.618, P < .0001) and cyclosporine A-based immunosuppression (β = −0.924, P < .0001) were negative predictors of AS. Conclusion: The data presented here showed that eGFR, low recipient age, low donor age, patient gender (male), and 3 HLA mismatches were correlated with long-term AS. In contrast, shorter AS was associated with the blood group B and cyclosporine A treatment. Cite this article as: Boran E, Boran M. Is the ABO blood group a predictor of renal allograft survival in ABO identical donor recipients?. Turk J Nephrol. 2021; 30(3): 213-217.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: The effect of the ABO blood group on renal allograft survival (AS) is unclear. We assessed the influence of the ABO blood group on AS and performed a comparative analysis of AS in kidney transplant recipients with different ABO blood groups. Methods: The 239 renal transplant recipients who underwent transplantation in a single center were stratified into the 3 groups: blood group O (84, 35.14%), blood group A (104, 43.51%), and due to the low number of blood group AB patients, blood groups B and AB were classified as blood group B (51, 21.3%). Clinical outcomes and patient demographics were investigated and compared between groups. Results: The AS of blood group O recipients was significantly longer than that of blood group B recipients (P = .001). Correlation analyses revealed that recipient age (P = .002), donor age (P = .013), creatinine level (P = .022), estimated glomerular filtration rate (eGFR) (P = .005), human leukocyte antigen (HLA) mismatches (P = .001), blood group O (P < .0001), blood group B (P < .0001), cyclosporine A (P < .0001), and sirolimus treatment (P = .032) were predictors of AS. Multivariate regression analyses indicated that blood group B (β = −0.618, P < .0001) and cyclosporine A-based immunosuppression (β = −0.924, P < .0001) were negative predictors of AS. Conclusion: The data presented here showed that eGFR, low recipient age, low donor age, patient gender (male), and 3 HLA mismatches were correlated with long-term AS. In contrast, shorter AS was associated with the blood group B and cyclosporine A treatment. Cite this article as: Boran E, Boran M. Is the ABO blood group a predictor of renal allograft survival in ABO identical donor recipients?. Turk J Nephrol. 2021; 30(3): 213-217.
Key concepts: ABO blood group system, Medicine, Internal medicine, ABO incompatibility, Immunology